Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Lantheus (LNTH)
Leerink Partners Maintains Lantheus(LNTH.US) With Buy Rating, Raises Target Price to $139
Earnings Preview: Lantheus to Report Financial Results Pre-market on May 07
8 Health Care Stocks Whale Activity In Today's Session
Express News | Lantheus Holdings Inc : Leerink Partners Raises Target Price to $139 From $132
William Blair Maintains Lantheus(LNTH.US) With Hold Rating
Lantheus Alzheimer's Diagnostic Candidate Shows Promise in Trials
Lantheus Holdings' Clinical-Stage F18-labeled Tau PET Radiodiagnostic, MK-6240, Meets Co-primary Endpoints In Two Pivotal Studies Assessing Sensitivity And Specificity
Express News | Lantheus Holdings Inc - Nda Submission for Mk-6240 Expected in Q3 2025
Express News | Lantheus Announces Alzheimer’s Disease Radiodiagnostic Mk-6240 Meets Co-Primary Endpoints in Two Pivotal Studies
Investors in Lantheus Holdings (NASDAQ:LNTH) Have Seen Fantastic Returns of 718% Over the Past Five Years
Unusual Options Activity: C, SCHW and Others Attract Market Bets, C V/OI Ratio Reaches 52.6
Fund Update: KEYBANK NATIONAL ASSOCIATION/OH Added 269,146 Shares of LANTHEUS HOLDINGS ($LNTH) to Their Portfolio
Lantheus Holdings, Inc. (LNTH): Among Stocks With Consistent Growth to Buy Now
Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Could Be 49% Below Their Intrinsic Value Estimate
TD Cowen Maintains Lantheus(LNTH.US) With Buy Rating, Maintains Target Price $110
Lantheus to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025, at 8:00 A.m. Eastern Time
Lantheus Stock Buy Rating Supported by Increased Pylarify Revenue Projections and Updated EPS Estimates
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
Is Lantheus Holdings (NASDAQ:LNTH) Using Too Much Debt?